LENZ THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
LENZ THERAPEUTICS, INC. (LENZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 526.36 thousand shares for the 3-month period ending 2021-09-30, per its 10-Q filed 2022-11-09.
Discontinued
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2022-11-09
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-09-30 was 526.36K shares, a 4.02% decline year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-06-30 was 2.48M shares.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-03-31 was 2.89M shares.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-09-30 was 548.38K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|
| 2021-09-30 | 526.36K shares 10-Q · filed 2022-11-09 | 3.00M shares derived: sum of 2 quarters · filed 2022-11-09 | 5.89M shares 10-Q · filed 2022-11-09 |
| 2021-06-30 | 2.48M shares 10-Q · filed 2022-08-11 | 5.37M shares 10-Q · filed 2022-08-11 | |
| 2021-03-31 | 2.89M shares 10-Q · filed 2022-05-12 | ||
| 2020-09-30 | 548.38K shares 10-Q · filed 2021-11-10 | 548.38K shares 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |